Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7837195 in Moderately to Severely Active Ulcerative Colitis
NCT06979336Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of RO7837195 in ulcerative colitis (UC) (5 arms), sponsored by Genentech. Primary endpoint: Clinical Remission at 12 weeks. Started Sep 2025; status: recruiting.
02
Drugs
RO7837195
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06979336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979336.